Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018-Reference-Cited by-同舟云学术

Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018

Published:2021-12-01 Issue:12 Volume:181 Page:1596
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Fu Mengyuan¹²,Naci Huseyin³,Booth Christopher M.⁴,Gyawali Bishal⁴,Cosgrove Austin¹,Toh Sengwee¹,Xu Ziyue²,Guan Xiaodong²,Ross-Degnan Dennis¹,Wagner Anita K.¹

Affiliation:

1. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts

2. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China

3. Department of Health Policy, London School of Economics and Political Science, London, UK

4. Division of Cancer Care and Epidemiology, Departments of Oncology and Public Health Sciences, Queen’s University Cancer Research Institute, Kingston, Canada

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Link

https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2785228/jamainternal_fu_2021_oi_210060_1638550201.61826.pdf

Reference53 articles.

1. Approval and regulation of pharmaceuticals, 1983-2018.;Darrow;JAMA,2020

2. Evolution of the onco-exceptionalism.;Del Paggio;JAMA Oncol,2021

3. Accelerated approval of cancer drugs—righting the ship of the US Food and Drug Administration.;DiMagno;JAMA Intern Med,2019

4. Assessment of the clinical benefit of cancer drugs receiving accelerated approval.;Gyawali;JAMA Intern Med,2019

5. Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials.;Chen;JAMA Intern Med,2019

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can Machine Learning Overcome the 95% Failure Rate and Reality that Only 30% of Approved Cancer Drugs Meaningfully Extend Patient Survival?;Journal of Medicinal Chemistry;2024-09-10

2. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis;The Lancet Oncology;2024-06

3. Financial impact of integrated specialty pharmacy efforts to avoid oral anticancer medication waste;Journal of Managed Care & Specialty Pharmacy;2024-05

4. Generating and using real-world data: A worthwhile uphill battle;Cell;2024-03

5. The impact of level of documentation on the accessibility and affordability of new drugs in Norway;Frontiers in Pharmacology;2024-02-14